Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy

American Journal of Gastroenterology

Volumn 102, Issue 10, 2007, Pages 2164-2170

  Cheon, Young Koog ^a   Cho, Young Deok ^a   Moon, Jong Ho ^a   Jang, Jae Young ^a   Kim, Young Seok ^a   Kim, Yun Soo ^b   Lee, Moon Sung ^a   Lee, Joon Seong ^a   Shim, Chan Sup ^a  

^a Soonchunhyang University College of Medicine   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HEMATOPORPHYRIN DERIVATIVE; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BILE DUCT CANCER; BILIARY TRACT DRAINAGE; BILIARY TRACT ENDOSCOPY; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOLOGICAL MARKERS; CHOLANGIOCARCINOMA; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PREDICTIVE VALUE OF TESTS; TUMOR BURDEN;

EID: 34848815007     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01403.x     Document Type: Article

References (20)

1. Steinberg W. The clinical utility of the CA 19-9 tumor associated antigen. Am J Gastroenterol 1990 85 : 350 5.
2. Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000 95 : 204 7.
3. Tabibzadeh SS, Poubouridis DP, May LT, et al. Interleukin-6 immunoreactivity in human tumors. Am J Pathol 1989 135 : 427 33.
4. Gallo O, Bani D, Toccafondi G, et al. Characterization of a novel cell line from pleomorphic adenoma of the parotid gland with myoepithelial phenotype and producing interleukin-6 as an autocrine growth factor. Cancer 1992 70 : 559 68.
5. Sehgal P. Interleukin-6: A regulator of plasma protein gene expression in hepatic and non-hepatic tissues. Mol Biol Med 1990 7 : 117 30.
6. Goydos JS, Brumfield AM, Frezza E, et al. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: Validation of utility as a clinical marker. Ann Surg 1998 227 : 398 404.
7. Okada K, Shimizu Y, Nambu S, et al. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol 1994 9 : 462 7.
8. Sugawara H, Yasoshima M, Katayanagi K, et al. Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma. Histopathology 1998 33 : 145 53.
9. Utsumi K, Takai Y, Tada T, et al. Enhanced production of IL-6 in tumor-bearing mice and determination of cells responsible for its augmented production. J Immunol 1990 145 : 397 403.
10. Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet 1975 140 : 170 8.
11. Ortner MA, Liebetruth J, Schreiber S, et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998 114 : 536 42.
12. Berr F, Wiedmann M, Tannapfel A, et al. Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival. Hepatology 2000 31 : 291 8.
13. Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: A randomized prospective study. Gastroenterology 2003 125 : 1355 63.
14. Shim CS, Cheon YK, Cha SW, et al. Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment. Endoscopy 2005 37 : 425 33.
15. Tangkijvanich P, Thong-ngam D, Theamboonlers A, et al. Diagnostic role of serum interleukin-6 and CA 19-9 in patients with cholangiocarcinoma. Hepatogastroenterology 2004 51 : 15 9.
16. Jaiswal M, LaRusso NF, Burgarr LJ, et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000 60 : 184 90.
17. Park J, Tadlock L, Gores GJ, et al. Inhibition of interleukin-6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 1999 30 : 1128 33.
18. Gores GJ. Cholangiocarcinoma: Current concepts and insights. Hepatology 2003 37 : 961 9.
19. Ducreux M, Liguory C, Lefebvre JF, et al. Management of malignant hilar biliary obstruction by endoscopy. Results and prognostic factors. Dig Dis Sci 1992 37 : 778 83.
20. Stoker J, Lameris JS, van Blankenstein M. Percutaneous metallic self-expandable endoprostheses in malignant hilar biliary obstruction. Gastrointest Endosc 1993 39 : 43 9.